InMode Ltd. reported a first-quarter 2026 profit of $11.6 million [1], with earnings of 18 cents per share [1].
The results demonstrate the company's ability to maintain profitability through cost-control measures while the broader aesthetic-device market experiences a downturn.
Headquartered in Yokneam, Israel, the medical-device company faced a challenging environment during the reporting period [2]. The company said its ability to remain in the black was due to continued demand for its products and internal efficiency efforts [3].
"We delivered solid results despite a challenging, soft market environment," CEO Miri Segal said [3].
The financial data for the first quarter of 2026 [1] indicates that InMode remains resilient compared to some of its peers in the micro- and small-cap sector. The company's adjusted earnings per share of 18 cents [1] reflect a stable operational baseline despite the volatility of the global aesthetic market.
Market analysts have noted the company's position within its asset class. Jim Simons said InMode is one of the best micro- and small-cap stocks to buy, even in a soft market [4].
InMode continues to operate its primary corporate functions from its Yokneam base [2]. The company has focused on balancing its growth strategy with the current economic headwinds affecting medical-device makers worldwide [3].
“InMode posted a profit of $11.6 million, or 18 cents per share, in Q1 2026.”
InMode's ability to post a profit during a market contraction suggests that its cost-management strategies are effectively offsetting lower industry demand. For the medical-device sector, this performance indicates that specialized aesthetic technology may retain a level of inelastic demand even when general market conditions soften.
